Regeneron Pharmaceuticals, Inc. (REGN) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Regeneron Pharmaceuticals, Inc. (REGN) Profile & Business Summary
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Key Information
| Ticker | REGN |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.regeneron.com |
Market Trend Overview for REGN
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-03-25 (ET)
As of 2026-03-25, REGN is showing signs of slowing down. Over the longer term, the trend remains bullish.
REGN last closed at 749.47. The price is about 0.4 ATR below its recent average price (758.86), and the market is currently in a trend that may be losing strength. Price at 749.47 is near light support around 746.66. Momentum may slow, while minor resistance sits near 771.23. View Support & Resistance from Options
The broader uptrend is still intact, but price has moved far from its recent average, increasing the risk of a pullback.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside level is near 720.80. If price falls below this area, the current upward trend would likely weaken or break.
On 2026-03-20, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-03-24] Price moved quickly and looked strong, but participation was limited.
Recent price action shows orderly upward progression with no major deterioration in bar-level efficiency. Structural conditions remain broadly constructive.
There was no clear sign of meaningful positions being carried into the overnight session.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is only slightly below the recent estimated cost basis of 754.07. Price is in the upper half of the main cost band (735.93 to 751.31), which is usually a healthier short-term location because price is holding the stronger side of recent trading activity. The higher up selling area sits around 755.50 to 761.09, so rebounds may begin to slow as price pushes into that zone. Recent positioning looks fairly balanced, with 46% in profit and 54% under water. From a trading point of view, the main question is whether rebounds remain healthy enough to reach and absorb the higher overhead supply zone.
Short Interest & Covering Risk for REGN
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 50%)
Structure Analysis
REGN Short positioning is starting to look crowded. Current days to cover is 3.8 trading days, meaning short positions would unwind somewhat slower than average. Short covering could add extra momentum to price moves. Early signs of positioning pressure are emerging (Fragility Score 44/100, DTC percentile 100%) with short positioning continuing to expand and liquidity contracting meaningfully (volume -32%). Short positioning is at extreme historical levels.
Risk Summary
Some early warning signs are emerging. Price strength remains intact, but underlying support may be starting to weaken.This indicator is intended as a risk filter, not a directional signal. A High or Extreme reading does not predict an immediate move, but suggests that if prices weaken, downside reactions may be more pronounced.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. In the latest reporting period, short interest continues to increase. Average trading volume is weakening, indicating contracting liquidity. Price action is compressing (range is tightening), which can make breaks more sensitive. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. Rising short pressure is occurring while liquidity is deteriorating. As a result, similar news or market events could lead to price moves about 2× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-02-27 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.